Balance Sheet Components (Tables)
|
3 Months Ended |
Mar. 31, 2026 |
|---|
| Balance Sheet Components [Abstract] |
|
| Summary of Available-for-sale Investments and Restricted Cash |
| | | | | | | | | | | | | March 31, 2026 | | | Amortized | | | Gross Unrealized | | | Estimated | | Cost | | Gains | | Losses | | | Fair Value | Assets | | | | | | | | | | | | Money market funds, included in cash equivalents | $ | 1,348 | | $ | — | | $ | — | | $ | 1,348 | Money market funds, included in restricted cash, non-current | | 4,702 | | | — | | | — | | | 4,702 | U.S. government securities | | 81,500 | | | — | | | (78) | | | 81,422 | U.S. treasury bills | | 19,864 | | | 1 | | | — | | | 19,865 | Corporate bonds/notes | | 63,517 | | | — | | | (153) | | | 63,364 | Agency bonds/notes | | 44,137 | | | — | | | (108) | | | 44,029 | Asset-backed securities | | 21,638 | | | — | | | (25) | | | 21,613 | Commercial paper | | 4,935 | | | — | | | (1) | | | 4,934 | Total | $ | 241,641 | | $ | 1 | | $ | (365) | | $ | 241,277 | | | | | | | | | | | | | Classified as: | | | | | | | | | | | | Cash equivalents | | | | | | | | | | $ | 1,348 | Short-term investments | | | | | | | | | | | 138,645 | Long-term investments | | | | | | | | | | | 96,582 | Restricted cash | | | | | | | | | | | 4,702 | Total | | | | | | | | | | $ | 241,277 |
| December 31, 2025 | | | Amortized | | | Gross Unrealized | | | Estimated | | Cost | | Gains | | Losses | | | Fair Value | Assets | | | | | | | | | | | | Money market funds, included in cash equivalents | $ | 27,806 | | $ | — | | $ | — | | $ | 27,806 | Money market funds, included in restricted cash, non-current | | 4,709 | | | — | | | — | | | 4,709 | U.S. government securities | | 81,385 | | | 94 | | | — | | | 81,479 | U.S. treasury bills | | 39,568 | | | 25 | | | | | | 39,593 | Corporate bonds/notes | | 57,564 | | | 19 | | | (12) | | | 57,571 | Agency bonds/notes | | 25,147 | | | 7 | | | (3) | | | 25,151 | Asset-backed securities | | 21,689 | | | 22 | | | — | | | 21,711 | Commercial paper | | 9,868 | | | 2 | | | — | | | 9,870 | Total | $ | 267,736 | | $ | 169 | | $ | (15) | | $ | 267,890 | | | | | | | | | | | | | Classified as: | | | | | | | | | | | | Cash equivalents | | | | | | | | | | $ | 27,806 | Short-term investments | | | | | | | | | | | 132,010 | Long-term investments | | | | | | | | | | | 103,365 | Restricted cash | | | | | | | | | | | 4,709 | Total | | | | | | | | | | $ | 267,890 |
|
| Summary of Fair Value of Cash Equivalents and Available-for-sale Investments Classified by Maturity |
| | | | | | | March 31, 2026 | | December 31, 2025 | Amounts maturing within one year | $ | 139,993 | | $ | 159,816 | Amounts maturing after one year through two years | | 96,582 | | | 103,365 | Total | $ | 236,575 | | $ | 263,181 |
|
| Schedule of Available-for-sale Investments in an Unrealized Loss Position |
| | | | | | | | | | | | | March 31, 2026 | | December 31, 2025 | | Less than 12 months | | Less than 12 months | | Fair Value | | Unrealized Loss | | Fair Value | | Unrealized Loss | Assets | | | | | | | | | | | | U.S. government securities | $ | 566 | | $ | (78) | | $ | — | | $ | — | Corporate bonds/notes | | 413 | | | (153) | | | 26,716 | | | (12) | Agency bonds/notes | | 389 | | | (108) | | | 3,995 | | | (3) | Asset-backed securities | | 47 | | | (25) | | | — | | | — | Commercial paper | | — | | | (1) | | | — | | | — | Total | $ | 1,415 | | $ | (365) | | $ | 30,711 | | $ | (15) |
|
| Schedule of Allowance for Credit Loss |
| | | | | | | | | | | | | March 31, | | December 31, | | 2026 | | 2025 | Balance at beginning of period | $ | 626 | | $ | 814 | Additions | | — | | | — | Write-offs | | — | | | (188) | Balance at end of period | $ | 626 | | $ | 626 |
|
| Summary of Prepaid Expenses and Other Current Assets |
| | | | | | | | | | | | | | | | | | | March 31, | | December 31, | | 2026 | | 2025 | Prepaid expenses | $ | 8,313 | | $ | 5,964 | Contract costs, current | | 8,202 | | | 6,669 | Other | | 1,472 | | | 1,442 | Total prepaid expenses and other current assets | $ | 17,987 | | $ | 14,075 |
|
| Schedule of Property and Equipment, Net |
| | | | | | | | | | | | | March 31, | | December 31, | | 2026 | | 2025 | Property and equipment at cost: | | | | | | Computer equipment and software | $ | 4,277 | | $ | 4,223 | Furniture, fixtures and equipment | | 2,280 | | | 2,114 | Capitalized internal-use software | | 13,624 | | | 12,529 | Leasehold improvements | | 2,095 | | | 2,086 | Construction in progress | | 1,481 | | | 140 | Total property and equipment | | 23,757 | | | 21,092 | Less: Accumulated depreciation and amortization | | (13,928) | | | (12,505) | Property and equipment, net | $ | 9,829 | | $ | 8,587 |
|
| Schedule of Other Non-Current Assets |
| | | | | | | | | | | | | March 31, | | December 31, | | 2026 | | 2025 | Contract costs, net | $ | 5,071 | | $ | 4,260 | Other | | 1,604 | | | 839 | Total other non-current assets | $ | 6,675 | | $ | 5,099 |
|
| Schedule of Accrued Expenses and Other Current Liabilities |
| | | | | | | | | | | | | March 31, | | December 31, | | 2026 | | 2025 | Accrued payroll and related expenses | $ | 19,762 | | $ | 28,150 | Customer contract and rebate liabilities | | 1,583 | | | 1,162 | Accrued royalty | | 1,049 | | | 864 | Accrued professional fees | | 821 | | | 627 | Accrued clinical trial expenses | | 1,118 | | | 550 | Other | | 1,553 | | | 1,926 | | $ | 25,886 | | $ | 33,279 |
|